Latest Insider Transactions at Iterum Therapeutics PLC (ITRM)
This section provides a real-time view of insider transactions for Iterum Therapeutics PLC (ITRM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Iterum Therapeutics plc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Iterum Therapeutics plc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 06
2024
|
Ronald Hunt |
BUY
Exercise of conversion of derivative security
|
Indirect |
247,934
+41.81%
|
-
|
|
Aug 06
2024
|
Corey N. Fishman Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
82,613
+37.61%
|
-
|
|
Aug 06
2024
|
Michael W. Dunne |
BUY
Exercise of conversion of derivative security
|
Direct |
106,247
+32.57%
|
-
|
|
Dec 22
2023
|
Michael W. Dunne |
BUY
Open market or private purchase
|
Direct |
25,000
+18.02%
|
$25,000
$1.4 P/Share
|
|
Dec 18
2023
|
Michael W. Dunne |
BUY
Open market or private purchase
|
Direct |
10,000
+10.13%
|
$10,000
$1.84 P/Share
|
|
Dec 01
2023
|
Sailaja Puttagunta Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,933
-22.05%
|
$5,866
$2.12 P/Share
|
|
Dec 01
2023
|
Sailaja Puttagunta Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,333
+38.52%
|
-
|
|
Nov 22
2023
|
Michael W. Dunne |
BUY
Open market or private purchase
|
Direct |
20,000
+20.25%
|
$40,000
$2.03 P/Share
|
|
Nov 20
2023
|
Corey N. Fishman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+15.52%
|
$10,000
$1.59 P/Share
|
|
Oct 01
2023
|
Michael W. Dunne |
BUY
Exercise of conversion of derivative security
|
Direct |
3,487
+5.6%
|
-
|
|
Oct 01
2023
|
Ronald Hunt |
BUY
Exercise of conversion of derivative security
|
Direct |
5,479
+27.64%
|
-
|
|
Jul 01
2023
|
Ronald Hunt |
BUY
Exercise of conversion of derivative security
|
Direct |
2,796
+23.97%
|
-
|
|
Jul 01
2023
|
Michael W. Dunne |
BUY
Exercise of conversion of derivative security
|
Direct |
1,779
+3.12%
|
-
|
|
Jun 15
2023
|
Mark Chin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,853
+46.41%
|
-
|
|
Jun 15
2023
|
Michael W. Dunne |
BUY
Exercise of conversion of derivative security
|
Direct |
15,853
+22.86%
|
-
|
|
Jun 15
2023
|
Beth Hecht Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,853
+45.7%
|
-
|
|
Apr 01
2023
|
Michael W. Dunne |
BUY
Exercise of conversion of derivative security
|
Direct |
1,299
+3.34%
|
-
|
|
Apr 01
2023
|
Ronald Hunt |
BUY
Exercise of conversion of derivative security
|
Direct |
2,041
+25.16%
|
-
|
|
Mar 11
2023
|
Corey N. Fishman Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,683
-11.34%
|
$0
$0.96 P/Share
|
|
Mar 11
2023
|
Corey N. Fishman Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,333
+22.23%
|
-
|
|
Mar 11
2023
|
Judith M. Matthews Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,883
-26.17%
|
$0
$0.96 P/Share
|
|
Mar 11
2023
|
Judith M. Matthews Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,666
+37.7%
|
-
|
|
Jan 01
2023
|
Ronald Hunt |
BUY
Exercise of conversion of derivative security
|
Direct |
1,197
+22.9%
|
-
|
|
Jan 01
2023
|
Michael W. Dunne |
BUY
Exercise of conversion of derivative security
|
Direct |
761
+2.05%
|
-
|
|
Dec 02
2022
|
Sailaja Puttagunta Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,365
-40.38%
|
$3,365
$1.32 P/Share
|
|
Dec 01
2022
|
Sailaja Puttagunta Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,334
+50.0%
|
-
|
|
Sep 20
2022
|
Brenton Karl Ahrens Director |
SELL
Open market or private sale
|
Indirect |
7,246
-100.0%
|
$7,246
$1.78 P/Share
|
|
Sep 19
2022
|
Brenton Karl Ahrens Director |
SELL
Open market or private sale
|
Indirect |
15,000
-67.43%
|
$15,000
$1.77 P/Share
|
|
Sep 16
2022
|
Brenton Karl Ahrens Director |
SELL
Open market or private sale
|
Indirect |
15,000
-40.27%
|
$15,000
$1.9 P/Share
|
|
Sep 15
2022
|
Brenton Karl Ahrens Director |
SELL
Open market or private sale
|
Indirect |
15,000
-28.71%
|
$30,000
$2.02 P/Share
|
|
Sep 14
2022
|
Brenton Karl Ahrens Director |
SELL
Open market or private sale
|
Indirect |
15,000
-22.31%
|
$30,000
$2.1 P/Share
|
|
Sep 13
2022
|
Brenton Karl Ahrens Director |
SELL
Open market or private sale
|
Indirect |
15,000
-18.24%
|
$30,000
$2.14 P/Share
|
|
Sep 12
2022
|
Brenton Karl Ahrens Director |
SELL
Open market or private sale
|
Indirect |
15,000
-15.42%
|
$30,000
$2.31 P/Share
|
|
Sep 09
2022
|
Brenton Karl Ahrens Director |
SELL
Open market or private sale
|
Indirect |
15,000
-13.36%
|
$30,000
$2.32 P/Share
|
|
Sep 08
2022
|
Brenton Karl Ahrens Director |
SELL
Open market or private sale
|
Indirect |
3,298
-2.85%
|
$6,596
$2.26 P/Share
|
|
Sep 07
2022
|
Michael W. Dunne |
BUY
Open market or private purchase
|
Direct |
10,000
+21.94%
|
$20,000
$2.22 P/Share
|
|
Jun 23
2022
|
Beth Hecht Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,798
+45.09%
|
-
|
|
Jun 23
2022
|
Michael W. Dunne |
BUY
Exercise of conversion of derivative security
|
Direct |
36,798
+8.75%
|
-
|
|
Jun 23
2022
|
Mark Chin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,798
+50.0%
|
-
|
|
Jun 23
2022
|
Ronald Hunt |
BUY
Exercise of conversion of derivative security
|
Direct |
36,798
+46.4%
|
-
|
|
Mar 25
2022
|
Michael W. Dunne |
BUY
Exercise of conversion of derivative security
|
Direct |
10,494
+2.94%
|
-
|
|
Mar 18
2022
|
Beth Hecht Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,642
+48.83%
|
-
|
|
Mar 14
2022
|
Judith M. Matthews Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
47,132
-36.64%
|
$0
$0.38 P/Share
|
|
Mar 11
2022
|
Corey N. Fishman Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
215,000
+28.59%
|
-
|
|
Mar 11
2022
|
Judith M. Matthews Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+43.74%
|
-
|
|
Jul 25
2021
|
Michael W. Dunne |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+19.21%
|
-
|
|
Feb 12
2021
|
Alexander J Denner > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,619,949
-100.0%
|
$21,239,898
$2.27 P/Share
|
|
Feb 11
2021
|
Alexander J Denner > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,000,000
-48.5%
|
$20,000,000
$2.59 P/Share
|
|
Feb 11
2021
|
Alexander J Denner > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
20,619,949
+50.0%
|
-
|
|
Feb 04
2021
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
11,651,597
+50.0%
|
-
|